KURA News and Press, Kura Oncology Inc. From 12/22/21

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Kura Oncology (KURA +0.8%) announces dose administration for the first patient in Phase 1/2 KURRENT clinical trial of tipifarnib in combination with Novartis’ alpelisib in patients with head and neck squamous cell carcinoma (HNSCC). The KURRENT trial is a biomarker-defined cohort ...

– Preclinical data suggest HRAS and PI3Kα are co-dependent oncogenes in HNSCC – – Combination has potential to address up to 50% of patients with HNSCC – – Initial cohort comprised of patients with PIK3CA-dependent HNSCC – SAN D...

– Overall response rate of 56% and median overall survival of 32.8 months in patients with advanced AITL, an aggressive form of T-cell lymphoma – – Results presented at ASH underscore potential of farnesyl transferase inhibition to drive clinical benefit in cancer...

SAN DIEGO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the presentation of new preclinical data for KO-539, the Company...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

The travel and leisure sector is recovering after news of a new COVID variant on Friday disrupted the holiday-shortened session. Of note, the Transportation Security Administration screened 85% of the number of people on Sunday than it did two years ago before the pandemic. Airline cancellati...

Retail stocks remained in focus during Wednesday's trading as Wall Street headed into the Thanksgiving holiday and the Black Friday kick-off to the annual Christmas shopping bonanza. Even as retailers prepare to enter their busiest time of year, a pair of weak earnings reports sparked a broad...

Shares of Kura Oncology (NASDAQ: KURA) , a clinical-stage biopharmaceutical company , are down sharply in response to a clinical hold for the company's experimental leukemia treatment. The stock was down 15.6% as of 11:20 a.m. ET on Wednesday. The Food and Drug Administratio...

Kura Oncology (NASDAQ:KURA) announces that the FDA has placed the KOMET-001 Phase 1b study of KO-539 in patients with relapsed or refractory acute myeloid leukemia (AML) on a partial clinical hold. Shares down 35.2% premarket at $10.75. The partial clinical hold was initiated follow...